Decidual stromal cells

Phase 2Biologic

KKarolinska Institutet

Decidual stromal cells is one of 53 biologic programs targeting Respiratory Failure. It is currently in Phase 2.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Respiratory FailureActive, not recruiting

Graft Versus Host DiseaseActive, not recruiting

Respiratory FailurePreclinical

Active, not recruiting

Graft Versus Host DiseasePhase 2

Active, not recruiting

Competition

Competitive Landscape

48 competitors in Graft Versus Host Disease

#DrugCompanyPhaseTrials

Trexall

Jazz Pharmaceuticals

Approved

15 2

Neoral

Novartis

Approved

9 3

Medrol

Pfizer

Approved

4 4

Selzentry

GSK

Approved

1 5

Gleevec

Nipent

Defitelio

Olumiant

Qvar

3 10

Cellcept

Roche

Phase 3

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Cystitis2 trials

A Double Blind Randomized Study Using Placenta Derived Decidual Stromal Cells for Hemorrhagic Cystitis

Unknown status·KKarolinska Institutet·Phase 2·NCT02174536·20 enrolled

A Pilot Study Using Placenta Derived Decidual Stromal Cells for Hemorrhagic Cystitis

Completed·KKarolinska Institutet·Phase 1/2·NCT02172963·12 enrolled

Respiratory Failure1 trial

Study of Decidual Stromal Cells to Treat COVID-19 Respiratory Failure

Completed·UUniversity Health Network, Toronto·N/A·NCT04451291·19 enrolled

Myelodysplastic Syndrome1 trial

Decidual Stromal Cells to Treat Graft-vs-Host Disease After Stem Cell Transplant for Myelodysplastic Syndrome/Myeloproliferative Neoplasm

Completed·UUniversity Health Network, Toronto·Phase 2·NCT04926194·1 enrolled

Acute Graft Versus Host Disease1 trial

Decidual Stromal Cells as Treatment for Acute Graft Versus Host Disease, a Phase 1-2 Study

Unknown status·KKarolinska Institutet·Phase 1/2·NCT02172937·50 enrolled

Toxicity1 trial

A Pilot Study Using Placenta Derived Decidual Stromal Cells for Toxicity and Inflammation With Special Focus to the Allogeneic Hematopoietic Cell Transplantation Setting

Unknown status·KKarolinska Institutet·Phase 1/2·NCT02175303·25 enrolled

1 more indication

Graft Versus Host Disease1 trial

A Randomized Phase II Study to Compare the Potential Long-Lasting Positive Effect of Decidual Stromal Cells to the Best Available Treatment in Graft Versus Host Disease

Active, not recruiting·UUniversity Health Network, Toronto·Phase 2·NCT05132166·50 enrolled

Sources

References

[1]
ClinicalTrials.gov — 7 trial records for Decidual stromal cells. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Decidual stromal cells compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Decidual stromal cells. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Karolinska Institutet company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Biologic[2]
Highest Phase: Phase 2[1]
Company: KKarolinska Institutet

Decidual stromal cells

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Cystitis2 trials

Respiratory Failure1 trial

Myelodysplastic Syndrome1 trial

Acute Graft Versus Host Disease1 trial

Toxicity1 trial

Graft Versus Host Disease1 trial

References

Drug Info

Quick Facts

Related News